Evidence map›Paper›PMID 25634354›Full record

ArticlePLoS genetics2015

MiR-24 is required for hematopoietic differentiation of mouse embryonic stem cells.

Lynn Roy, Emmanuel Bikorimana, Danica Lapid, Hyewon Choi, Tan Nguyen, Richard Dahl

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. [Tribbles pseudokinase 3 inhibits the adipogenic differentiation of human adipose-derived mesenchymal stem cells].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2020
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Lynn RoyHarper Cancer Research Institute, South Bend, Indiana, United States of America; Microbiology and Immunology, Indiana University School of Medicine, South Bend, Indiana, United States of America.
Emmanuel BikorimanaHarper Cancer Research Institute, South Bend, Indiana, United States of America; Microbiology and Immunology, Indiana University School of Medicine, South Bend, Indiana, United States of America.
Danica LapidDept. of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, United States of America.
Hyewon ChoiDept. of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, United States of America.
Tan NguyenHarper Cancer Research Institute, South Bend, Indiana, United States of America; Microbiology and Immunology, Indiana University School of Medicine, South Bend, Indiana, United States of America.
Richard DahlHarper Cancer Research Institute, South Bend, Indiana, United States of America; Microbiology and Immunology, Indiana University School of Medicine, South Bend, Indiana, United States of America; Dept. of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, United States of America.
University of Notre Dame · USIndiana University · USMike and Josie Harper Cancer Research Institute

Funding

Regulating hematopoietic stem cells and hematopoiesis for clinical efficacyP30DK090948 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI BROXMEYER, HAL E., SROUR, EDWARD F · 2010 to 2014
$3.7M
NIDDK NIH HHS 5P30DK090948NIDDK NIH HHS P30 DK090948
6 · The paper itself

Abstract

Overexpression of miRNA, miR-24, in mouse hematopoietic progenitors increases monocytic/ granulocytic differentiation and inhibits B cell development. To determine if endogenous miR-24 is required for hematopoiesis, we antagonized miR-24 in mouse embryonic stem cells (ESCs) and performed in vitro differentiations. Suppression of miR-24 resulted in an inability to produce blood and hematopoietic progenitors (HPCs) from ESCs. The phenotype is not a general defect in mesoderm production since we observe production of nascent mesoderm as well as mesoderm derived cardiac muscle and endothelial cells. Results from blast colony forming cell (BL-CFC) assays demonstrate that miR-24 is not required for generation of the hemangioblast, the mesoderm progenitor that gives rise to blood and endothelial cells. However, expression of the transcription factors Runx1 and Scl is greatly reduced, suggesting an impaired ability of the hemangioblast to differentiate. Lastly, we observed that known miR-24 target, Trib3, is upregulated in the miR-24 antagonized embryoid bodies (EBs). Overexpression of Trib3 alone in ESCs was able to decrease HPC production, though not as great as seen with miR-24 knockdown. These results demonstrate an essential role for miR-24 in the hematopoietic differentiation of ESCs. Although many miRNAs have been implicated in regulation of hematopoiesis, this is the first miRNA observed to be required for the specification of mammalian blood progenitors from early mesoderm.

Indexed as

AnimalsBasic Helix-Loop-Helix ProteinsCell Cycle ProteinsCell DifferentiationColony-Forming Units AssayCore Binding Factor Alpha 2 SubunitEmbryo, MammalianEmbryonic Stem CellsEndothelial CellsFlow CytometryGene Expression Regulation, DevelopmentalHematopoiesisMiceMicroRNAsProto-Oncogene ProteinsT-Cell Acute Lymphocytic Leukemia Protein 1Basic Helix-Loop-Helix ProteinsCell Cycle ProteinsCore Binding Factor Alpha 2 SubunitMicroRNAsMirn24 microRNA, mouseProto-Oncogene ProteinsRunx1 protein, mouseTal1 protein, mouseT-Cell Acute Lymphocytic Leukemia Protein 1TRB3 protein, mouse

Identifiers

PMID25634354
PMCPMC4310609
OpenAlexW2031030362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.